At close of trading yesterday, Mylan (NASDAQ:MYL) was down 6.9 percent, Teva (NYSE:TEVA) had lost 9.5 percent and Endo International (TSX:ENL) dropped close to twenty percent.
“White hat” hackers can test cyber vulnerabilities of connected medical devices without fear of legal repercussion.
Another pharmaceutical manufacturer is under scrutiny by US lawmakers: Reckitt Benckiser faces a lawsuit from some 35 states for its pricing of Suboxone.
Short seller Muddy Waters Capital has reiterated allegations of cybersecurity vulnerability with St. Jude Medical’s cardiac devices.
Pfizer’s Senior Principal Scientist, Min-Jean Yin, has quietly left the company following allegations of data manipulation in several of her published papers.
Johnson & Johnson is warning customers that its Animas OneTouch Ping Insulin pump can be hacked—a cybersecurity vulnerability that could be deadly.
Healthcare stocks on the S&P 500 fell more than one percent just prior to the presidential debate—a sure sign of investor unease. But what happened the next day?
Is naloxone the next drug that will bring a pharmaceutical executive before Congress? The life-saving medication can now cost $2,000 per dose.
St. Jude Medical saw its stock fall four percent after Muddy Waters published a report alleging that the medical device manufacturer had serious cyber security issues. Now, St. Jude is striking back with a lawsuit its CEO calls “critical to the entire medical device ecosystem.”
Reuters reported that Zimbabwe’s Chamber of Mines has advised the country to cut royalties for platinum miners Anglo American Platinum (JSE:AMS) and Impala Platinum (JSE:IMP).
Andrew Miller of Benchmark Mineral Intelligence shares his thoughts on what Volkswagen’s electric vehicle announcement could mean for demand for the raw materials needed to make electric vehicle batteries.
Reuters reported that according to the London Bullion Market Association (LBMA), exchanges, brokers and data vendors are interested in making the gold market more liquid and transparent by providing clearing or reporting services.
Writing for Seeking Alpha, Hebba Investments, explores the idea of whether or not the time is right for investing in palladium. The author notes that palladium prices have fallen drastically in 2015, but states, “we think there is plenty of opportunity in palladium as the recent price drop is not